Text Size

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
VaxInnate Corporation
ClinicalTrials.gov Identifier:
NCT01560793
First received: February 14, 2012
Last updated: May 23, 2013
Last verified: May 2013
History of Changes
  Purpose

This study will evaluate the safety and immunogenicity of VAX161B [STF2.HA5 H5N1], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.


Condition Intervention Phase
Influenza
 Biological: VAX161 [STF2.HA5 H5N1]
 Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Resource links provided by NLM:

MedlinePlus related topics: Bird Flu Flu
U.S. FDA Resources

Further study details as provided by VaxInnate Corporation:

Primary Outcome Measures:
  • Safety [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Assess safety, reactogenicity and tolerability. Symptoms will be collected from the memory aid and from the information collected at the clinic visits. All symptoms will be graded according to severity. Response to vaccine will be categorized as local (arm pain, redness, bruising, etc.) or systemic (headache, muscle aches, fatigue, etc.) symptoms. Laboratory tests such as CRP, WBC, LFTs and cytokines collected before and after vaccination will also be analyzed. We will compare the types and severity of symptoms and laboratory results based on vaccine dose.


Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: 6 mos. ] [ Designated as safety issue: No ]
    To assess serum immune response, sera collected at Days 0, 21, 42 and 180 will be analyzed for HAI, MN, serum IgG anti-HA and serum IgG anti-flagellin by Elisa. The geometric mean, seroconversion and seroprotection rates will be determined.


Estimated Enrollment: 200
Study Start Date: June 2012
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: VAX161B
Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
 Biological: VAX161 [STF2.HA5 H5N1]
dose escalating, 2 intramuscular doses given 21 days apart

Detailed Description:

The purpose of this study is to test an investigational vaccine known as "VAX161B". VAX161B is a vaccine for the influenza A virus subtype H5N1 avian influenza virus (bird flu). In this study, the subject will receive the VAX161B vaccine at one of five doses to see which does might be the best. VaxInnate want to find out how safe these vaccines are and how well they are tolerated by people who receive them. To measure how effective each type of vaccine is, VaxInnate will test the ability of the body to develop an immune response, which means how well the body recognizes and defends itself against the influenza virus.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • male or female aged 18 - 49 years inclusive
  • give written informed consent to participate
  • healthy, as determined by medical history, physical examination
  • comprehension of the study requirements
  • willing to provide multiple blood specimens collected by venipuncture.

Exclusion Criteria:

  • Subjects who have a psychiatric illness, a chronic illness that would interfere with participation or interpretation of results
  • clinically significant abnormal liver function tests
  • positive serology for HBsAg or HCV antibodies
  • impaired immune responses
  • history of anaphylactic type reaction to injected vaccines
  • history of drug or chemical abuse in the year prior to screening
  • history of Guillain-Barré Syndrome
  • history of chronic obstructive pulmonary disease or history of other lung disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01560793

Locations
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33143
United States, Kansas
Johnson County Clin-Trials
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
VaxInnate Corporation
Investigators
Principal Investigator: Eric Sheldon, MD Miami Research Associates
Principal Investigator: Casey Johnson, DO Johnson County Clin-Trials
  More Information

No publications provided

Responsible Party: VaxInnate Corporation
ClinicalTrials.gov Identifier: NCT01560793     History of Changes
Other Study ID Numbers: VAX161-01B
Study First Received: February 14, 2012
Last Updated: May 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by VaxInnate Corporation:
Influenza
Vaccines
H5N1

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
 Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013